Transforming Off-the-Shelf Therapies from the Start
How far can the allogeneic cell therapy field progress without high-quality starting material and robust donor selection processes?Â
The 3rd Donor Selection & Cell Source Summit returns to San Diego this November to address these key challenges.
As the leading platform for allogeneic biopharma, academia, starting material suppliers, and other service providers, this summit brings together key stakeholders to share insights on navigating the challenges of consistency, safety, and efficacy when using donor-derived starting material. It will also drive forward new approaches to recruitment and retention, with the shared goal of ensuring a consistent and reliable supply of starting material required for clinical trials.
Meet 2025 Partners & Solution Providers:
Overcome Top Industry Challenges, Including:
1
Struggling to Nail Characterization Testing?
Join ImmuneBridge as they highlight their use of computational tools to screen donors and identify top performers that drive precision, speed and consistency in allogeneic therapies.
2
Uncertain About the Investment Landscape?
Join Allogene Therapeutics in their interactive roundtable discussion to put your questions to the room and brainstorm solutions with the experts who are successfully navigating investor questions and concerns around cell and gene therapies.
3
Looking to Understand More About Other Companies' Starting Material Use?
Join Luminary Therapeutics and Genentech as they share case studies on their methods and steps taken to manage inter- and intra-donor variability across a variety of starting material types including iPSCs, PBMCs, and cord blood.
Join Discussions with KOL's, Including:
I appreciate the intimacy of the conference size, which fosters more dialogue and interaction with fellow participants''
Senior Manager - Process Data Systems & Analytics, AlloVir - 2023 Attendee
Companies Attending:
